Loading...

Repligen

DB:RGN
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RGN
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
RGN Share Price and Events
7 Day Returns
5%
DB:RGN
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
60.2%
DB:RGN
-5.6%
DE Biotechs
-4.5%
DE Market
RGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Repligen (RGN) 5% -3.7% 2% 60.2% 106.7% 337.4%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • RGN outperformed the Biotechs industry which returned -5.6% over the past year.
  • RGN outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
RGN
Industry
5yr Volatility vs Market

RGN Value

 Is Repligen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Repligen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Repligen.

DB:RGN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:RGN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (4.18%))
1.336
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.34
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.336 * 5.96%)
8.19%

Discounted Cash Flow Calculation for DB:RGN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Repligen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:RGN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.19%)
2019 35.74 Analyst x4 33.04
2020 42.67 Analyst x4 36.46
2021 51.87 Analyst x3 40.96
2022 62.84 Analyst x1 45.87
2023 82.55 Analyst x1 55.70
2024 95.20 Est @ 15.32% 59.37
2025 105.47 Est @ 10.79% 60.80
2026 113.52 Est @ 7.62% 60.48
2027 119.65 Est @ 5.4% 58.93
2028 124.26 Est @ 3.85% 56.56
Present value of next 10 years cash flows $508.15
DB:RGN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $124.26 × (1 + 0.23%) ÷ (8.19% – 0.23%)
$1,564.61
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,564.61 ÷ (1 + 8.19%)10
$712.22
DB:RGN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $508.15 + $712.22
$1,220.38
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,220.38 / 44.07
$27.69
DB:RGN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:RGN represents 0.88335x of NasdaqGS:RGEN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88335x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 27.69 x 0.88335
€24.46
Value per share (EUR) From above. €24.46
Current discount Discount to share price of €49.64
= -1 x (€49.64 - €24.46) / €24.46
-102.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Repligen is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Repligen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Repligen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $0.38
NasdaqGS:RGEN Share Price ** NasdaqGS (2019-04-25) in USD $56.19
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Repligen.

DB:RGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RGEN Share Price ÷ EPS (both in USD)

= 56.19 ÷ 0.38

148x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Repligen is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Repligen is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Repligen's expected growth come at a high price?
Raw Data
DB:RGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 148x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
27%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

DB:RGN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 148x ÷ 27%

5.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Repligen is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Repligen's assets?
Raw Data
DB:RGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $14.02
NasdaqGS:RGEN Share Price * NasdaqGS (2019-04-25) in USD $56.19
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:RGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RGEN Share Price ÷ Book Value per Share (both in USD)

= 56.19 ÷ 14.02

4.01x

* Primary Listing of Repligen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Repligen is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Repligen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Repligen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RGN Future Performance

 How is Repligen expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Repligen expected to grow at an attractive rate?
  • Repligen's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Repligen's earnings growth is expected to exceed the Germany market average.
  • Repligen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RGN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 27%
DB:RGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 14%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 479 1
2022-12-31 345 2
2021-12-31 288 75 44 4
2020-12-31 247 62 30 8
2019-12-31 221 55 24 8
DB:RGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 194 33 17
2018-09-30 184 42 23
2018-06-30 171 21 23
2018-03-31 155 18 29
2017-12-31 141 17 28
2017-09-30 125 4 21
2017-06-30 113 5 18
2017-03-31 110 12 13
2016-12-31 105 8 12
2016-09-30 100 9 7
2016-06-30 96 17 8
2016-03-31 88 14 8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Repligen's earnings are expected to grow significantly at over 20% yearly.
  • Repligen's revenue is expected to grow by 14% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Repligen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 1.00 1.00 1.00 1.00
2021-12-31 0.87 0.92 0.82 2.00
2020-12-31 0.63 0.73 0.54 5.00
2019-12-31 0.50 0.52 0.46 5.00
DB:RGN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 0.38
2018-09-30 0.53
2018-06-30 0.53
2018-03-31 0.71
2017-12-31 0.74
2017-09-30 0.59
2017-06-30 0.52
2017-03-31 0.39
2016-12-31 0.35
2016-09-30 0.21
2016-06-30 0.25
2016-03-31 0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Repligen is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Repligen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Repligen has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RGN Past Performance

  How has Repligen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Repligen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Repligen's year on year earnings growth rate has been positive over the past 5 years.
  • Repligen's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Repligen's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Repligen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Repligen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 194.03 16.62 65.69 15.82
2018-09-30 183.70 23.16 64.06 15.74
2018-06-30 170.75 23.03 63.20 14.14
2018-03-31 155.48 28.73 57.14 10.22
2017-12-31 141.24 28.35 51.51 8.67
2017-09-30 125.22 21.21 42.95 7.64
2017-06-30 113.32 17.69 33.82 7.53
2017-03-31 110.04 13.12 31.17 7.56
2016-12-31 104.54 11.68 30.85 7.36
2016-09-30 100.39 6.92 27.50 6.75
2016-06-30 95.53 8.30 27.59 6.35
2016-03-31 87.82 8.04 25.30 5.71
2015-12-31 83.54 9.35 24.70 5.74
2015-09-30 78.48 8.68 23.20 5.64
2015-06-30 73.95 7.61 20.89 5.80
2015-03-31 68.04 6.82 18.98 5.98
2014-12-31 63.55 8.17 16.34 5.61
2014-09-30 62.54 11.90 14.73 5.70
2014-06-30 66.08 16.32 13.98 5.48
2014-03-31 68.04 18.03 12.78 6.36
2013-12-31 68.17 16.09 12.70 7.34
2013-09-30 71.60 22.32 12.59 8.02
2013-06-30 67.88 18.24 12.81 9.02
2013-03-31 65.90 15.27 13.11 9.62
2012-12-31 62.27 14.16 13.23 10.49
2012-09-30 50.62 2.44 14.24 11.02
2012-06-30 44.14 1.24 13.61 11.66

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Repligen has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Repligen used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Repligen's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Repligen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Repligen has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RGN Health

 How is Repligen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Repligen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Repligen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Repligen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Repligen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Repligen Company Filings, last reported 3 months ago.

DB:RGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 615.57 103.49 193.82
2018-09-30 606.49 102.40 190.30
2018-06-30 598.66 101.33 175.61
2018-03-31 597.18 100.28 173.88
2017-12-31 591.55 99.25 173.76
2017-09-30 576.87 98.23 159.67
2017-06-30 190.94 97.23 144.95
2017-03-31 176.79 96.24 141.84
2016-12-31 168.76 95.27 141.78
2016-09-30 166.52 94.32 178.71
2016-06-30 163.72 93.38 181.80
2016-03-31 128.89 0.00 69.70
2015-12-31 122.75 0.00 71.77
2015-09-30 121.45 0.00 68.87
2015-06-30 118.22 0.00 63.17
2015-03-31 111.93 0.00 54.47
2014-12-31 111.73 0.00 58.45
2014-09-30 114.59 0.00 54.08
2014-06-30 115.56 0.00 50.03
2014-03-31 108.85 0.00 70.76
2013-12-31 103.89 0.00 61.62
2013-09-30 100.16 0.00 62.99
2013-06-30 92.45 0.00 58.15
2013-03-31 87.41 0.00 47.91
2012-12-31 84.12 0.00 40.06
2012-09-30 73.70 0.00 30.31
2012-06-30 68.73 0.00 28.38
  • Repligen's level of debt (16.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 16.8% today).
  • Debt is well covered by operating cash flow (31.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 5.4x coverage).
X
Financial health checks
We assess Repligen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Repligen has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RGN Dividends

 What is Repligen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Repligen dividends.
If you bought €2,000 of Repligen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Repligen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Repligen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Repligen has not reported any payouts.
  • Unable to verify if Repligen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Repligen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Repligen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Repligen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Repligen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Repligen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RGN Management

 What is the CEO of Repligen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony Hunt
COMPENSATION $3,044,785
AGE 54
TENURE AS CEO 3.9 years
CEO Bio

Mr. Anthony J. Hunt, also known as Tony, has been the Chief Executive Officer and President of Repligen Corporation since May 21, 2015. Mr. Hunt served as Secretary of Repligen Corporation. He served as Chief Operating Officer of Repligen Corporation since May 6, 2014 until May 21, 2015. Mr. Hunt served as President of BioProduction at Life Technologies. He played a key role in the development and growth of Life Technologies's bioprocessing business, where he focused on expanding the upstream Gibco(R) cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt oversee commercial and manufacturing operations for Repligen. He joined Life Technologies in 2008, first as General Manager, BioProduction Chromatography and Pharma Analytics before being named President, BioProduction in 2011. In this most recent role, where he led an organization of approximately 200 employees, his responsibilities included commercial operations and research and development, as well as product management and marketing. Prior to this role, Mr. Hunt was with Applied Biosystems for eight years, served as Senior Director, Pharma Programs where he launched the pharma analytics business that in 2008 became a part of the bioproduction platform at Life Technologies. Mr. Hunt began his career with Repligen where he was involved in process development. He has been Director of Repligen Corporation since May 2015 and has been its Member of Scientific Advisory Board since March 2016. He received a Bachelors of Science degree in microbiology from University College Galway, Ireland, a Masters of Science degree in biotechnology from University College Galway, Ireland and a Masters of Business Administration from Boston University School of Management.

CEO Compensation
  • Tony's compensation has been consistent with company performance over the past year.
  • Tony's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Repligen management team in years:

3.2
Average Tenure
55
Average Age
  • The tenure for the Repligen management team is about average.
Management Team

Tony Hunt

TITLE
CEO, President
COMPENSATION
$3M
AGE
54
TENURE
3.9 yrs

Jon Snodgres

TITLE
CFO & Secretary
COMPENSATION
$1M
AGE
52
TENURE
4.8 yrs

Steve Curran

TITLE
Vice President of Global Operations

Sondra Newman

TITLE
Senior Director of Investor Relations

Stephen Tingley

TITLE
Vice President of Sales
TENURE
2.3 yrs

Rachel Goodrich

TITLE
Vice President of Marketing
TENURE
2.1 yrs

Ken Elmer

TITLE
Global Head of Human Resources
TENURE
2.3 yrs

Ralf Kuriyel

TITLE
Senior Vice President of Research & Development
AGE
59
TENURE
2.5 yrs

Tony MacDonald

TITLE
Senior Vice President of Ultrafiltration & Diafiltration
AGE
56
TENURE
15.3 yrs

Gustav Silfversparre

TITLE
Vice President of Operations - Repligen Sweden
TENURE
6.1 yrs
Board of Directors Tenure

Average tenure and age of the Repligen board of directors in years:

4.4
Average Tenure
65
Average Age
  • The tenure for the Repligen board of directors is about average.
Board of Directors

Karen Dawes

TITLE
Chairperson
COMPENSATION
$275K
AGE
66
TENURE
7.3 yrs

Tony Hunt

TITLE
CEO, President
COMPENSATION
$3M
AGE
54
TENURE
3.9 yrs

Glenn Cooper

TITLE
Director
COMPENSATION
$155K
AGE
65
TENURE
9.7 yrs

Glenn Muir

TITLE
Director
COMPENSATION
$174K
AGE
59
TENURE
3.5 yrs

Thomas Ryan

TITLE
Director
COMPENSATION
$154K
AGE
76
TENURE
15.6 yrs

Alfred Goldberg

TITLE
Member of Scientific Advisory Board
COMPENSATION
$16K
AGE
75
TENURE
3.1 yrs

John Cox

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$149K
AGE
55
TENURE
5.4 yrs

Nicolas Barthelemy

TITLE
Director
COMPENSATION
$339K
AGE
52
TENURE
4.8 yrs

Charlie Cooney

TITLE
Member of Scientific Advisory Board
AGE
74
TENURE
3.1 yrs

Steven Cramer

TITLE
Member of Scientific Advisory Board
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • Repligen insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Mar 19 Sell Jon Snodgres Individual 25. Mar 19 25. Mar 19 -6,467 €52.19 €-334,646
20. Mar 19 Sell Anthony Hunt Individual 18. Mar 19 18. Mar 19 -14,550 €53.74 €-765,426
04. Mar 19 Sell Jon Snodgres Individual 28. Feb 19 28. Feb 19 -1,875 €51.70 €-96,942
04. Mar 19 Sell Anthony Hunt Individual 28. Feb 19 28. Feb 19 -7,475 €51.82 €-387,330
04. Mar 19 Sell Ralf Kuriyel Individual 28. Feb 19 28. Feb 19 -185 €51.95 €-9,610
05. Mar 19 Sell Anthony Hunt Individual 05. Mar 19 05. Mar 19 -13,000 €51.77 €-673,043
05. Mar 19 Sell Ralf Kuriyel Individual 05. Mar 19 05. Mar 19 -2,240 €51.80 €-116,030
05. Mar 19 Sell Jon Snodgres Individual 05. Mar 19 05. Mar 19 -2,645 €51.79 €-136,985
20. Dec 18 Sell Ralf Kuriyel Individual 18. Dec 18 18. Dec 18 -311 €47.90 €-14,896
06. Nov 18 Sell Thomas Ryan Individual 05. Nov 18 05. Nov 18 -1,763 €57.66 €-101,662
12. Sep 18 Sell Anthony Hunt Individual 10. Sep 18 10. Sep 18 -15,693 €49.72 €-780,199
31. Aug 18 Sell Nicolas Barthelemy Individual 29. Aug 18 29. Aug 18 -2,154 €46.54 €-100,255
29. Aug 18 Sell Jon Snodgres Individual 28. Aug 18 28. Aug 18 -14,460 €45.06 €-651,527
24. Aug 18 Sell Thomas Ryan Individual 22. Aug 18 22. Aug 18 -2,366 €44.36 €-104,964
13. Aug 18 Sell Roy Eddleman Individual 09. Aug 18 09. Aug 18 -116,073 €42.93 €-4,978,255
08. Aug 18 Sell Roy Eddleman Individual 06. Aug 18 08. Aug 18 -53,927 €42.27 €-2,279,587
07. Jun 18 Sell Thomas Ryan Individual 06. Jun 18 06. Jun 18 -1,932 €37.65 €-72,748
22. May 18 Sell Anthony Hunt Individual 21. May 18 21. May 18 -16,249 €36.16 €-587,640
18. May 18 Sell Roy Eddleman Individual 16. May 18 16. May 18 -118,850 €35.70 €-4,242,517
10. May 18 Sell Roy Eddleman Individual 08. May 18 09. May 18 -120,000 €34.38 €-4,110,629
X
Management checks
We assess Repligen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Repligen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RGN News

Simply Wall St News

RGN Company Info

Description

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell alternating tangential flow systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius tangential flow filters line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH and Sartorius Stedim Biotech to develop multiple affinity ligands. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Details
Name: Repligen Corporation
RGN
Exchange: DB
Founded: 1981
$2,223,417,813
44,073,998
Website: http://www.repligen.com
Address: Repligen Corporation
Building 1,
Suite 100,
Waltham,
Massachusetts, 02453,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RGEN Common Stock Nasdaq Global Select US USD 29. Apr 1986
DB RGN Common Stock Deutsche Boerse AG DE EUR 29. Apr 1986
Number of employees
Current staff
Staff numbers
548
Repligen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 20:39
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.